Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciforadenant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 20/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 15/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 15/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 14/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciforadenant SCHEMBL19063945 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| Ciforadenant SCHEMBL29470561 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| Ciforadenant SCHEMBL29350253 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| Ciforadenant SCHEMBL29470579 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| Ciforadenant SCHEMBL18679938 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL19655024 | 0.92 | ADORA2A (0.85) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL19063740 | 0.89 | ADORA2A (0.80) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL19065764 | 0.89 | ADORA2A (0.80) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL25979393 | 0.89 | ADORA2A (0.80) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL31733947 | 0.88 | ADORA2A (0.79) | ADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683923-A1 | HYDROGEN SULFATE COMPLEXES, INCLUDING SALTS, CRYSTALLINE FORMS, AND HYDRATES AND SOLVATES OF ENT1 INHIBITORS | iTeos Belgium SA (BE) | 2026-01-28 | — | — | EP | claimed |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2025-02-20 | — | — | US | claimed |
| EP-3393475-B1 | CIFORADENT ALONE OR IN COMBINATION WITH ATEZOLIZUMAB FOR USE IN TREATING CANCER | CORVUS PHARMACEUTICALS INC (US) | 2025-02-05 | — | — | EP | claimed |
| US-12116635-B2 | Methods for detecting and treating cancers having adenosine pathway activation | CORVUS PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | claimed |
| WO-2024194392-A1 | MULTICOMPONENT COMPLEXES, INCLUDING SALTS AND CRYSTALLINE COMPLEXES, OF ENT1 INHIBITORS | iTeos Belgium SA (BE) | 2024-09-26 | — | — | WO | claimed |
| WO-2024194391-A1 | HYDROGEN SULFATE COMPLEXES, INCLUDING SALTS, CRYSTALLINE FORMS, AND HYDRATES AND SOLVATES OF ENT1 INHIBITORS | iTeos Belgium SA (BE) | 2024-09-26 | — | — | WO | claimed |
| EP-4413004-A1 | MACROCYCLIC COMPOUNDS HAVING ENT1 INHIBITING ACTIVITY | iTeos Belgium SA (BE) | 2024-08-14 | — | — | EP | claimed |
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | INCYTE CORPORATION (US) | 2024-08-13 | — | — | US | claimed |
| US-12023337-B2 | Methods of treating cancer | CORVUS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | claimed |
| US-20240141060-A1 | DOSAGE REGIMES FOR ANTI-CD73 AND ANTI-ENTPD2 ANTIBODIES AND USES THEREOF | NOVARTIS AG (CH) | 2024-05-02 | — | — | US | claimed |
| EP-3642240-A1 | ANTIBODY MOLECULES TO CD73 AND USES THEREOF | Novartis AG (CH) | 2020-04-29 | — | — | EP | claimed |
| WO-2018237157-A1 | ANTIBODY MOLECULES TO CD73 AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-27 | — | — | WO | claimed |
| WO-2018237173-A1 | ANTIBODY MOLECULES TO CD73 AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-27 | — | — | WO | claimed |
| US-9376443-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2016-06-28 | — | — | US | claimed |
| US-20150291602-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2015-10-15 | — | — | US | claimed |
| US-8987279-B2 | Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2015-03-24 | — | — | US | claimed |
| US-20130245044-A1 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2013-09-19 | — | — | US | claimed |
| US-8450328-B2 | Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2013-05-28 | — | — | US | claimed |
| EP-2321321-B1 | TRIAZOLO [4, 5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS R&D LTD (GB) | 2012-02-08 | — | — | EP | claimed |
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2011-07-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | ADORA2A 11/4885ADORA2B 19/4885ADORA1 15/4885 |
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | ADORA2A, ADORA2B, NT5E | ADORA2A 1/4885ADORA2B 2/4885ADORA1 10/4885 |
| US-20240141060-A1 | DOSAGE REGIMES FOR ANTI-CD73 AND ANTI-ENTPD2 ANTIBODIES AND USES THEREOF | ENTPD1, ENTPD2, ENTPD5 | ADORA2A 7/4885ADORA2B 29/4885ADORA1 17/4885 |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | ADORA2A, ADORA2B, NT5E | ADORA2A 1/4885ADORA2B 2/4885ADORA1 10/4885 |
| US-12023337-B2 | Methods of treating cancer | ADORA2A, PRKAB1, PRKAG1 | ADORA2A 1/4885ADORA2B 18/4885ADORA1 12/4885 |
| US-12116635-B2 | Methods for detecting and treating cancers having adenosine pathway activation | ENTPD3, ENTPD1, ENTPD8 | ADORA2A 68/4885ADORA2B 133/4885ADORA1 306/4885 |
| US-20150291602-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | ADORA2A 11/4885ADORA2B 19/4885ADORA1 15/4885 |
| US-20130245044-A1 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | ADORA2A 11/4885ADORA2B 19/4885ADORA1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.